Skip to search formSkip to main contentSkip to account menu

PF-05280014

Known as: Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar ABP 980, Herceptin Trastuzumab Biosimilar PF-05280014 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Antibodies, Monoclonal, Humanizedtrastuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
.
OBJECTIVE To compare the pharmacokinetic (PK) profiles, immunogenicity, and safety of the proposed biosimilar IBI305 with those… 
2018
2018
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching
We read with great interest the recently published results from DANBIO registry on switching from originator etanercept (ETA) to… 
2018
2018
P607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients
2017
2017
A phase 1 study comparing the proposed biosimilar BS‐503a with bevacizumab in healthy male volunteers
This is a randomized, double‐blind, single‐dose, parallel group phase 1 study to assess pharmacokinetic similarity, safety, and… 
Review
2016
Review
2016
Update on Brazilian biosimilar enoxaparins
ABSTRACT Introduction: Brazil is among the first countries approving the commercialization and clinical use of biosimilar… 
2015
2015
Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
BACKGROUND Epoetin-zeta (epoetin-ζ) (sold as Retacrit™/Silapo™) is a biologic product that was approved by the European Medicines… 
2014
2014
Structural and functional analyses of biosimilar enoxaparins available in Brazil
Summary Biosimilar enoxaparins have been available for clinical use in Brazil since 2009. Although their use has reduced costs of… 
2013
2013
A phase I pharmacokinetics trial comparing PF-05280014 (a potential biosimilar) and trastuzumab in healthy volunteers (REFLECTIONS B327-01).
171 Background: PF-05280014, a proposed biosimilar to trastuzumab, has an identical amino acid sequence and similar… 
2013
2013
THU0208 Comparative, Randomized, Simple Blind to Evaluate Efficacy and Safety of Infinitam® (Etanercept), Associated with Methotrexate Compared with Enbrel® (Etanercept) Associated with Methotrexate…
Background Tumor necrosis factor alpha (TNFa) is a proinflammatory cytokine than its synthesis increases in patients with… 
2011
2011
Next generation and biosimilar monoclonal antibodies: Essential considerations towards regulatory acceptance in Europe; February 3-4, 2011; Freiburg, Germany
The “Next Generation and Biosimilar Monoclonal Antibodies: Essential Considerations Towards Regulatory Acceptance in Europe… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)